<30% decrease in PSMA-VOL ± new sites of PSMA-positive or PSMA-negative tumor or <20% increase in PSMA-VOL ± new sites of PSMA-positive or PSMA-negative tumor or PR with new lesions or PD without new lesions. The gene discussed is FOLH1; the disease is neoplasm.